Ndlovu, HonestLawal, Ismaheel OpeyemiKabunda, JosephKaoma, ChimbabantuMashigoane, KgomotsoKnoesen, ZaneRamonaheng, KeamogetsweSibiya, SandileMdlophane, Amanda H.Mdanda, SiphoEbenhan, ThomasKgatle, MankgopoZeevaart, Jan RijnMokoala, Kgomotso M.G.Al-Ibraheem, AkranSathekge, Mike Machaba2026-01-162026-01-162025-06Ndlovu, H., Lawal, I.O., Kabunda, J. et al. Targeted alpha therapy in prostate cancer: review of available agents in clinical practice. Quarterly Journal of Nuclear Medicine and Molecular Imaging 2025; 69: 118-128. DOI : 10.23736/S1824-4785.25.03642-8.1824-4785 (print)1827-1936 (online)DOI : 10.23736/S1824-4785.25.03642-8http://hdl.handle.net/2263/107375Targeted alpha therapy (TAT) has shown promise in prostate cancer patients, both hormone-sensitive and castration-resistant, with or without prior treatment. TAT's radiobiological properties explain why it is more potent than other forms of ionizing radiation, such as the clinically approved [177Lu]Lu-PSMA-617. Although most TAT agents used in compassionate care or clinical trials target the prostate-specific membrane antigen (PSMA), some alternatives are yet to be used clinically, some of which aim to address PSMA-negative prostate cancer. These include [223Ra]RaCl2, which is approved for palliative bone pain, and a variety of other non-PSMA antigen or receptor-targeting medicines. Whereas this study focuses on TAT medicines that are currently available for clinical use, it also explores these preclinical agents.en© 2025 © 2025 Edizioni Minerva Medica.Prostatic neoplasmsFOLH 1 proteinHumanTargeted alpha therapy (TAT)Prostate-specific membrane antigen (PSMA)Clinical protocolsArticle